Close

China Ticks BeiGene PD-1, Can Novartis Bloom In US, Europe

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...
- Advertisement -

Last year, Novartis chose to purchase its way into the arena after the failure of its PD-1/L1 candidate, spartalizumab. So it reached a deal with China’s BeiGene, paying $650 million up front and promising $1.55 billion in milestone payments in exchange for a fraction of its PD-1 antibody tislelizumab. While Novartis has yet to see any benefits from the agreement, its Chinese partner continues to make waves.

BeiGene received approval in China for tislelizumab as a second-line treatment for patients with locally progressed or metastatic esophageal squamous cell carcinoma. The approval is for people who are resistant to first-line chemotherapy or those who have seen their condition worsen following chemo. Tislelizumab is being evaluated for the same purpose in both the United States and Europe. The FDA approved Novartis’ biologics licence for the treatment of ESCC, the most frequent kind of throat cancer and the sixth-leading cause of cancer deaths worldwide, in September.

BeiGene has received seven additional approvals for tislelizumab in its home country, including four for non-small cell lung cancer. The first was for third-line Hodgkin’s lymphoma in 2019. Following that, a nod was given for bladder cancer that had already been treated. Outside of China, the medicine still has to get approval. It aids the body’s immune cells in detecting and fighting malignancies.

The approval of tislelizumab is based on the findings of a phase 3 trial that demonstrated a 30% decreased risk of death and a 2.3-month increase in patient survival when compared to the chemotherapy drug docetaxel. Even if they are able to take care of the ESCC market in the U.S. and Europe, it will be quite an uphill task for BeiGene and Novartis to challenge Merck’s entrenched Keytruda and Bristol-Myers Squibb’s Opdivo.

Pricing may be the key, however. In looking for approval for the Innovent-partnered PD-1 med Tyvyt, Eli Lilly offered it at a big discount in the U.S. That drug failed to score an FDA nod, but offering discounts is one way for late market entrants to gain share.

Pricing, on the other hand, could be the deciding factor. In order to gain clearance for the PD-1 drug Tyvyt, which was developed in collaboration with Innovent, Eli Lilly provided it at a steep discount in the United States. Although that medicine did not receive FDA approval, providing discounts is one strategy for late market entrants to obtain market share.

Never miss a pharmaceutical headline

The pharmaceutical industry moves fast – stay on top of it with our must - read briefings.

  • The top pharma and life sciences stories, straight to your inbox
  • The biggest news, features, interviews, and analysis
  • Dedicated coverage of the key developments driving the global pharmaceutical sector

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Latest stories

Related stories

Insulated Pallet Protection in Temperature-Sensitive Pharmaceutical Shipping

In the pharmaceutical industry, products frequently require very specific...

Litmys and PharmaACE Establish Strategic Partnership for Market Projections

Life sciences consulting firms Litmys and PharmaACE have officially...

Blackstone Provides Up to $1.5 Billion for Pfizer’s Obesity Drug Candidate

Private equity firm Blackstone Life Sciences has agreed to...

How Biopharmaceutical Research Is Shaping the Future of Cancer Treatment

Cancer is no longer viewed solely as a clinical...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Translate »